Sarepta Therapeutics, Inc. SRPT
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.97B | 2.18B | 2.20B | 2.41B | 2.48B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.97B | 2.18B | 2.20B | 2.41B | 2.48B |
| Cost of Revenue | 1.60B | 1.71B | 2.36B | 1.97B | 1.92B |
| Gross Profit | 377.26M | 470.80M | -163.43M | 443.83M | 565.14M |
| SG&A Expenses | 436.74M | 467.04M | 491.72M | 527.29M | 563.60M |
| Depreciation & Amortization | 2.76M | 2.71M | 2.62M | 2.55M | 2.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.04B | 2.18B | 2.86B | 2.50B | 2.48B |
| Operating Income | -62.24M | 1.05M | -657.77M | -86.01M | -932.00K |
| Income Before Tax | -130.92M | 24.47M | -702.23M | -252.19M | -24.13M |
| Income Tax Expenses | 5.81M | -40.59M | 11.19M | 19.33M | 33.83M |
| Earnings from Continuing Operations | -136.73 | 65.06 | -713.41 | -271.51 | -57.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.73M | 65.06M | -713.41M | -271.51M | -57.96M |
| EBIT | -62.24M | 1.05M | -657.77M | -86.01M | -932.00K |
| EBITDA | -17.53M | 46.18M | -613.25M | -36.28M | 40.15M |
| EPS Basic | -1.39 | 0.67 | -7.08 | -2.73 | -0.58 |
| Normalized Basic EPS | -0.66 | -0.14 | -4.08 | -0.49 | 0.07 |
| EPS Diluted | -1.67 | 0.26 | -7.21 | -2.89 | -0.76 |
| Normalized Diluted EPS | -0.94 | -0.48 | -4.14 | -0.67 | -0.11 |
| Average Basic Shares Outstanding | 415.45M | 408.02M | 400.40M | 391.89M | 387.04M |
| Average Diluted Shares Outstanding | 432.38M | 433.57M | 409.02M | 412.70M | 412.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |